<DOC>
	<DOCNO>NCT01961726</DOCNO>
	<brief_summary>A phase I/II study evaluate safety efficacy JVS-100 administer retrograde delivery cohort adult Ischemic Heart Failure .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy JVS-100 Administered Adults With Ischemic Heart Failure</brief_title>
	<detailed_description>72 subject ischemic cardiomyopathy . The Phase I portion ( n=12 subject ) open label . In first cohort , six subject receive single dose 30 mg JVS-100 minimum 3 day enrollment . After seven day follow enrollment last patient cohort 1 , safety assessment DSMC perform . Upon DSMC approval , second cohort six subject receive single dose 45 mg JVS-100 minimum 3 day enrollment . After seven day follow enrollment last patient cohort 2 , safety assessment DSMC perform . Upon DSMC approval , 60 subject randomize ( 1:1:1 ) receive single dose 30 mg 45 mg JVS-100 matching placebo .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Willing able sign inform consent Greater equal 18 year age Poor quality life measure Minnesota Living Heart Failure Questionnaire ( MLWHFQ ) Impaired 6 Minute Walk test Ischemic cardiomyopathy without acute coronary syndrome within last 6 month Residual welldemarcated region LV systolic dysfunction define least 3 consecutive segment abnormal wall motion echocardiography read echocardiography core laboratory LVEF le equal 40 % measure echocardiography read echocardiography core laboratory Subject receive stable optimal pharmacological therapy define : ACE inhibitor and/or ARB , Betablocker 90 day stable dose* 30 day unless contraindicate Diuretic subject evidence fluid retention ASA unless contraindicate Statin unless contraindicate Aldosterone antagonist per physician discretion Subject must permanent device place coronary sinus time enrollment *As define 50 % change dose Planned revascularization within 30 day follow enrollment Note : angiographic study perform within last year subject enrol , angiography study report include part subject 's file Estimated Glomerular Filtration Rate &lt; 30 ml/min* Signs acute heart failure within 24 hour schedule infusion History aortic valve regurgitation classify `` moderatesevere '' bad Patients exclude : Known prior trauma coronary sinus In dwell instrumentation may hamper coronary venous catheterization , include biventricular pacing coronary sinus lead Mitral regurgitation define `` severe '' measure echocardiography clinical site Patients plan mitral valve repair replacement surgery Any patient history cancer exclude unless : The cancer limit curable nonmelanoma skin malignancy and/or The cancer remove successful tumor resection , without radiation chemotherapy treatment , 5 year prior enrollment study without recurrence . Subjects persistent ( per ACC/AHA/EEC guideline ) 53 , define recurrent AF episodes lasting longer 7 day ) chronic atrial fibrillation exclude unless : A stable , regular heart rate maintain biventricular pacemaker A stable , regular heart rate maintain univentricular pacemaker pace less equal 40 % time Inability undergo 6 minute walk treadmill exercise test Previous solid organ transplant Subjects great 40 % univentricular RV Pacing Subjects uncontrolled diabetes define HbA1c &gt; 10 % Participation experimental clinical trial within 30 day prior enrollment Life expectancy less 1 year Positive pregnancy test ( serum Î²HCG ) woman childbearing potential and/or unwillingness use contraceptives limit sexual activity describe Section 8.2.1 Unwillingness men capable father child agree use barrier contraception limit sexual activity describe Section 8.2.1 Subjects breast feeding Subjects positive test result hepatitis B/C and/or HIV exclude unless : The subject carrier hepatitis B/C never active flare Subjects history Systemic Lupus Erythematosus ( SLE ) flare Total Serum Bilirubin &gt; 4.0 mg/dl Aspartate aminotransferase ( AST ) &gt; 120 IU/L Alanine aminotransferase ( ALT ) &gt; 135 IU/L Alkaline phosphatase ( ALP ) : &gt; 300 IU/L Clinically significant elevation PT PTT relative laboratory norm day 0 Critical limb ischemia limit patient complete 6 minute walk treadmill test Subjects severe chronic obstructive pulmonary disease ( COPD ) Severe define hospitalize COPD within last 12 month Any subject requiring home oxygen use treatment symptom COPD History drug alcohol abuse within last year A subject exclude he/she unfit trial base discretion site Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>